NL-OMON45312已完成不适用
*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)* - MaRaBoo study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy military volunteers that received a completed intradermal immunization last year or 2 years ago.
排除标准
- •- Age < 18 years;
- •- No previous booster immunization;
- •- No previous post-exposition treatment with HRIG;
- •- Potential deployment to rabies endemic area within study period ;
- •- Presence of a serious medical history with a potential effect on the immune system such
- •as diabetes mellitus, HIV, functional or hyposplenia/asplenia;
- •- Allergies to one of the components of the rabies vaccine such as chicken egg protein,
- •polygeline, hypersensitivity to neomycin, chlortetracycline, amphotericin B and other
- •antibiotics of the same class;
- •- Use of mefloquine or chloroquine during the study period ;
- •- Pregnancy ;
- •- Breastfeeding;
- •- Immune compromised due to medication such as prednisolone, TNF-alfa inhibitors,
- •*biologicals* or immunodeficiency due to humoral or cellular cause.
研究者
相似试验
已完成
不适用
Rabies antibody respons after booster vaccination, > 10 years after pre-exposure scheme (RAR-boost study)Rabies10047438NL-OMON47356Academisch Medisch Centrum29
已完成
不适用
Validation of the Dutch version of the Hip Outcome ScoreNL-OMON47747Reinier de Graaf Groep136
已完成
不适用
An international, non-drug interventional, real-world cohort of PAH patients newly initiating PAH therapy with guideline-directed assessments of disease severityIncreased bloodpressure in the arteries of the lung1001928010038716Pulmonary arterial hypertensionNL-OMON52230Actelion Pharmaceuticals12
已完成
不适用
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNL-OMON49382AbbVie B.V.2
已完成
2 期
A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta ThalassemiaBeta Thalassemiainherited blood disorder10038158NL-OMON54921IMARA, Inc.15